{
"info": {
"nct_id": "NCT00767520",
"official_title": "A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI)",
"inclusion_criteria": "* Histologically-documented invasive estrogen receptor positive breast cancer , with tumor tissue from prior surgery available for analysis\n* Prior therapy with a non-steroidal aromatase inhibitor\n* Recurrent or progressive advanced breast cancer (locally-advanced or metastatic)\n* Documented breast cancer with tumor ≤ 28 days prior to study entry\n* Women who are NOT of childbearing potential\n* Must be able to take oral medication\n* Performance Status 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Pleural or pericardial effusion or ascites (of any etiology; Grade ≥ 1) within 6 months prior to study entry\n* Any chemotherapy, immunotherapy < 6 months before study entry. Any targeted therapy (eg. lapatinib) < 6 months before study entry, unless given in combination with an NSAI\n* Any antitumor therapy, including radiotherapy or hormonal therapy, within 15 days prior to study entry\n* Prior exposure to exemestane, any Src-family kinase inhibitor including dasatinib, to agents intended to control osteolytic disease other than bisphosphonates, or to any investigational agent for breast cancer\n* Concurrent or previous malignant disease requiring chemotherapy or radiation treatment within the prior 3 years\n* Significant bleeding disorder, or ongoing or recent clinically-significant gastrointestinal bleeding\n* Any serious cardiac condition, including congestive heart failure or myocardial infarction within 6 months, uncontrolled angina, or Class III or IV heart disease as defined by the New York Heart Association, baseline ejection fraction ≤ 40%, diagnosed congenital long QT syndrome, clinically-significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes), QTc interval > 450 msec at baseline (Fridericia correction)\n* Hematologic abnormality Grade ≥ 2\n* Hypocalcemia of Grade ≥ 1\n* Any Chemistry abnormality of Grade ≥ 2 [except Grade 2 indirect bilirubin permitted if diagnosed Gilbert's disease]\n* Pregnant Women and Women of Childbearing Potential (WOCBP)\n* Extremely lactose intolerant, in the judgment of treating physician (100 mg dasatinib contains 135 mg lactose, posing a problem only if intolerance is severe)\n* Receiving any of the following concomitant medications: Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes including: (Subjects must discontinue drug use at least 7 days prior to starting dasatinib)\n* Potent inhibitors of CYP3A4 isoenzyme\n* Prisoners or subjects who are involuntarily incarcerated; or subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "* Histologically-documented invasive estrogen receptor positive breast cancer , with tumor tissue from prior surgery available for analysis",
"criterions": [
{
"exact_snippets": "Histologically-documented invasive estrogen receptor positive breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "histology",
"expected_value": "invasive"
}
},
{
"exact_snippets": "Histologically-documented invasive estrogen receptor positive breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "receptor status",
"expected_value": "estrogen receptor positive"
}
},
{
"exact_snippets": "tumor tissue from prior surgery available for analysis",
"criterion": "tumor tissue",
"requirement": {
"requirement_type": "availability",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Histologically-documented invasive estrogen receptor positive breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "histology",
"expected_value": "invasive"
}
},
{
"exact_snippets": "Histologically-documented invasive estrogen receptor positive breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "receptor status",
"expected_value": "estrogen receptor positive"
}
}
]
},
{
"exact_snippets": "tumor tissue from prior surgery available for analysis",
"criterion": "tumor tissue",
"requirement": {
"requirement_type": "availability",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Prior therapy with a non-steroidal aromatase inhibitor",
"criterions": [
{
"exact_snippets": "Prior therapy with a non-steroidal aromatase inhibitor",
"criterion": "prior therapy",
"requirement": {
"requirement_type": "type",
"expected_value": "non-steroidal aromatase inhibitor"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Prior therapy with a non-steroidal aromatase inhibitor",
"criterion": "prior therapy",
"requirement": {
"requirement_type": "type",
"expected_value": "non-steroidal aromatase inhibitor"
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* Any chemotherapy, immunotherapy < 6 months before study entry. Any targeted therapy (eg. lapatinib) < 6 months before study entry, unless given in combination with an NSAI",
"criterions": [
{
"exact_snippets": "Any chemotherapy, immunotherapy < 6 months before study entry.",
"criterion": "chemotherapy, immunotherapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<",
"value": 6,
"unit": "months"
}
}
},
{
"exact_snippets": "Any targeted therapy (eg. lapatinib) < 6 months before study entry, unless given in combination with an NSAI",
"criterion": "targeted therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<",
"value": 6,
"unit": "months"
}
}
},
{
"exact_snippets": "Any targeted therapy (eg. lapatinib) < 6 months before study entry, unless given in combination with an NSAI",
"criterion": "targeted therapy",
"requirement": {
"requirement_type": "combination with NSAI",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Any chemotherapy, immunotherapy < 6 months before study entry.",
"criterion": "chemotherapy, immunotherapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<",
"value": 6,
"unit": "months"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Any targeted therapy (eg. lapatinib) < 6 months before study entry, unless given in combination with an NSAI",
"criterion": "targeted therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<",
"value": 6,
"unit": "months"
}
}
},
{
"not_criteria": {
"exact_snippets": "Any targeted therapy (eg. lapatinib) < 6 months before study entry, unless given in combination with an NSAI",
"criterion": "targeted therapy",
"requirement": {
"requirement_type": "combination with NSAI",
"expected_value": true
}
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Any antitumor therapy, including radiotherapy or hormonal therapy, within 15 days prior to study entry",
"criterions": [
{
"exact_snippets": "Any antitumor therapy, including radiotherapy or hormonal therapy, within 15 days prior to study entry",
"criterion": "antitumor therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">",
"value": 15,
"unit": "days"
}
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Any antitumor therapy, including radiotherapy or hormonal therapy, within 15 days prior to study entry",
"criterion": "antitumor therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">",
"value": 15,
"unit": "days"
}
}
}
}
},
{
"identified_line": {
"line": "* Concurrent or previous malignant disease requiring chemotherapy or radiation treatment within the prior 3 years",
"criterions": [
{
"exact_snippets": "Concurrent or previous malignant disease",
"criterion": "malignant disease",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "requiring chemotherapy or radiation treatment",
"criterion": "chemotherapy or radiation treatment",
"requirement": {
"requirement_type": "necessity",
"expected_value": true
}
},
{
"exact_snippets": "within the prior 3 years",
"criterion": "time since treatment",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": "<=",
"value": 3,
"unit": "years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Concurrent or previous malignant disease",
"criterion": "malignant disease",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "requiring chemotherapy or radiation treatment",
"criterion": "chemotherapy or radiation treatment",
"requirement": {
"requirement_type": "necessity",
"expected_value": true
}
}
]
},
{
"exact_snippets": "within the prior 3 years",
"criterion": "time since treatment",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": "<=",
"value": 3,
"unit": "years"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Significant bleeding disorder, or ongoing or recent clinically-significant gastrointestinal bleeding",
"criterions": [
{
"exact_snippets": "Significant bleeding disorder",
"criterion": "bleeding disorder",
"requirement": {
"requirement_type": "severity",
"expected_value": "significant"
}
},
{
"exact_snippets": "ongoing or recent clinically-significant gastrointestinal bleeding",
"criterion": "gastrointestinal bleeding",
"requirement": {
"requirement_type": "status",
"expected_value": [
"ongoing",
"recent"
]
}
},
{
"exact_snippets": "ongoing or recent clinically-significant gastrointestinal bleeding",
"criterion": "gastrointestinal bleeding",
"requirement": {
"requirement_type": "severity",
"expected_value": "clinically-significant"
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Significant bleeding disorder",
"criterion": "bleeding disorder",
"requirement": {
"requirement_type": "severity",
"expected_value": "significant"
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "ongoing or recent clinically-significant gastrointestinal bleeding",
"criterion": "gastrointestinal bleeding",
"requirement": {
"requirement_type": "status",
"expected_value": [
"ongoing",
"recent"
]
}
},
{
"exact_snippets": "ongoing or recent clinically-significant gastrointestinal bleeding",
"criterion": "gastrointestinal bleeding",
"requirement": {
"requirement_type": "severity",
"expected_value": "clinically-significant"
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Any serious cardiac condition, including congestive heart failure or myocardial infarction within 6 months, uncontrolled angina, or Class III or IV heart disease as defined by the New York Heart Association, baseline ejection fraction ≤ 40%, diagnosed congenital long QT syndrome, clinically-significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes), QTc interval > 450 msec at baseline (Fridericia correction)",
"criterions": [
{
"exact_snippets": "serious cardiac condition, including congestive heart failure",
"criterion": "serious cardiac condition",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "myocardial infarction within 6 months",
"criterion": "myocardial infarction",
"requirement": {
"requirement_type": "time since event",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "months"
}
}
},
{
"exact_snippets": "uncontrolled angina",
"criterion": "uncontrolled angina",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Class III or IV heart disease as defined by the New York Heart Association",
"criterion": "Class III or IV heart disease",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "baseline ejection fraction ≤ 40%",
"criterion": "baseline ejection fraction",
"requirement": {
"requirement_type": "value",
"expected_value": {
"operator": "<=",
"value": 40,
"unit": "%"
}
}
},
{
"exact_snippets": "diagnosed congenital long QT syndrome",
"criterion": "congenital long QT syndrome",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "clinically-significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes)",
"criterion": "clinically-significant ventricular arrhythmias",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "QTc interval > 450 msec at baseline (Fridericia correction)",
"criterion": "QTc interval",
"requirement": {
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 450,
"unit": "msec"
}
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "serious cardiac condition, including congestive heart failure",
"criterion": "serious cardiac condition",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "myocardial infarction within 6 months",
"criterion": "myocardial infarction",
"requirement": {
"requirement_type": "time since event",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "months"
}
}
}
]
},
{
"exact_snippets": "uncontrolled angina",
"criterion": "uncontrolled angina",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Class III or IV heart disease as defined by the New York Heart Association",
"criterion": "Class III or IV heart disease",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "baseline ejection fraction ≤ 40%",
"criterion": "baseline ejection fraction",
"requirement": {
"requirement_type": "value",
"expected_value": {
"operator": "<=",
"value": 40,
"unit": "%"
}
}
},
{
"exact_snippets": "diagnosed congenital long QT syndrome",
"criterion": "congenital long QT syndrome",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "clinically-significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes)",
"criterion": "clinically-significant ventricular arrhythmias",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "QTc interval > 450 msec at baseline (Fridericia correction)",
"criterion": "QTc interval",
"requirement": {
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 450,
"unit": "msec"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Hematologic abnormality Grade ≥ 2",
"criterions": [
{
"exact_snippets": "Hematologic abnormality Grade ≥ 2",
"criterion": "hematologic abnormality",
"requirement": {
"requirement_type": "grade",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "N/A"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Hematologic abnormality Grade ≥ 2",
"criterion": "hematologic abnormality",
"requirement": {
"requirement_type": "grade",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "N/A"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Hypocalcemia of Grade ≥ 1",
"criterions": [
{
"exact_snippets": "Hypocalcemia of Grade ≥ 1",
"criterion": "hypocalcemia",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "Grade"
}
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Hypocalcemia of Grade ≥ 1",
"criterion": "hypocalcemia",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "Grade"
}
}
}
}
},
{
"identified_line": {
"line": "* Any Chemistry abnormality of Grade ≥ 2 [except Grade 2 indirect bilirubin permitted if diagnosed Gilbert's disease]",
"criterions": [
{
"exact_snippets": "Chemistry abnormality of Grade ≥ 2",
"criterion": "chemistry abnormality",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "Grade"
}
}
},
{
"exact_snippets": "Grade 2 indirect bilirubin permitted if diagnosed Gilbert's disease",
"criterion": "indirect bilirubin",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": "=",
"value": 2,
"unit": "Grade"
}
}
},
{
"exact_snippets": "Grade 2 indirect bilirubin permitted if diagnosed Gilbert's disease",
"criterion": "indirect bilirubin",
"requirement": {
"requirement_type": "diagnosis",
"expected_value": "Gilbert's disease"
}
}
]
},
"logical_structure": {
"condition": {
"and_criteria": [
{
"exact_snippets": "Grade 2 indirect bilirubin permitted if diagnosed Gilbert's disease",
"criterion": "indirect bilirubin",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": "=",
"value": 2,
"unit": "Grade"
}
}
},
{
"exact_snippets": "Grade 2 indirect bilirubin permitted if diagnosed Gilbert's disease",
"criterion": "indirect bilirubin",
"requirement": {
"requirement_type": "diagnosis",
"expected_value": "Gilbert's disease"
}
}
]
},
"then_criteria": null,
"else_criteria": {
"exact_snippets": "Chemistry abnormality of Grade ≥ 2",
"criterion": "chemistry abnormality",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "Grade"
}
}
}
}
},
{
"identified_line": {
"line": "* Extremely lactose intolerant, in the judgment of treating physician (100 mg dasatinib contains 135 mg lactose, posing a problem only if intolerance is severe)",
"criterions": [
{
"exact_snippets": "Extremely lactose intolerant",
"criterion": "lactose intolerance",
"requirement": {
"requirement_type": "severity",
"expected_value": "extreme"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Extremely lactose intolerant",
"criterion": "lactose intolerance",
"requirement": {
"requirement_type": "severity",
"expected_value": "extreme"
}
}
]
}
},
{
"identified_line": {
"line": "* Receiving any of the following concomitant medications: Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes including: (Subjects must discontinue drug use at least 7 days prior to starting dasatinib)",
"criterions": [
{
"exact_snippets": "Receiving any of the following concomitant medications: Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes",
"criterion": "concomitant medications",
"requirement": {
"requirement_type": "category",
"expected_value": "Category I drugs"
}
},
{
"exact_snippets": "Receiving any of the following concomitant medications: Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes",
"criterion": "concomitant medications",
"requirement": {
"requirement_type": "risk",
"expected_value": "causing Torsades de Pointes"
}
},
{
"exact_snippets": "Subjects must discontinue drug use at least 7 days prior to starting dasatinib",
"criterion": "discontinuation of drug use",
"requirement": {
"requirement_type": "time before starting dasatinib",
"expected_value": {
"operator": ">=",
"value": 7,
"unit": "days"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Receiving any of the following concomitant medications: Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes",
"criterion": "concomitant medications",
"requirement": {
"requirement_type": "category",
"expected_value": "Category I drugs"
}
},
{
"exact_snippets": "Receiving any of the following concomitant medications: Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes",
"criterion": "concomitant medications",
"requirement": {
"requirement_type": "risk",
"expected_value": "causing Torsades de Pointes"
}
}
]
},
{
"not_criteria": {
"exact_snippets": "Subjects must discontinue drug use at least 7 days prior to starting dasatinib",
"criterion": "discontinuation of drug use",
"requirement": {
"requirement_type": "time before starting dasatinib",
"expected_value": {
"operator": ">=",
"value": 7,
"unit": "days"
}
}
}
}
]
}
},
{
"identified_line": {
"line": "* Potent inhibitors of CYP3A4 isoenzyme",
"criterions": [
{
"exact_snippets": "Potent inhibitors of CYP3A4 isoenzyme",
"criterion": "CYP3A4 isoenzyme inhibitors",
"requirement": {
"requirement_type": "potency",
"expected_value": "potent"
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Potent inhibitors of CYP3A4 isoenzyme",
"criterion": "CYP3A4 isoenzyme inhibitors",
"requirement": {
"requirement_type": "potency",
"expected_value": "potent"
}
}
}
},
{
"identified_line": {
"line": "* Prisoners or subjects who are involuntarily incarcerated; or subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness",
"criterions": [
{
"exact_snippets": "Prisoners or subjects who are involuntarily incarcerated",
"criterion": "incarceration status",
"requirement": {
"requirement_type": "status",
"expected_value": "involuntarily incarcerated"
}
},
{
"exact_snippets": "subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness",
"criterion": "detention status",
"requirement": {
"requirement_type": "status",
"expected_value": "compulsorily detained"
}
},
{
"exact_snippets": "subjects who are compulsorily detained for treatment of either a psychiatric ... illness",
"criterion": "psychiatric illness",
"requirement": {
"requirement_type": "treatment",
"expected_value": "compulsorily detained"
}
},
{
"exact_snippets": "subjects who are compulsorily detained for treatment of either a ... physical (eg, infectious disease) illness",
"criterion": "physical illness",
"requirement": {
"requirement_type": "treatment",
"expected_value": "compulsorily detained"
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Prisoners or subjects who are involuntarily incarcerated",
"criterion": "incarceration status",
"requirement": {
"requirement_type": "status",
"expected_value": "involuntarily incarcerated"
}
},
{
"exact_snippets": "subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness",
"criterion": "detention status",
"requirement": {
"requirement_type": "status",
"expected_value": "compulsorily detained"
}
}
]
},
{
"or_criteria": [
{
"exact_snippets": "subjects who are compulsorily detained for treatment of either a psychiatric ... illness",
"criterion": "psychiatric illness",
"requirement": {
"requirement_type": "treatment",
"expected_value": "compulsorily detained"
}
},
{
"exact_snippets": "subjects who are compulsorily detained for treatment of either a ... physical (eg, infectious disease) illness",
"criterion": "physical illness",
"requirement": {
"requirement_type": "treatment",
"expected_value": "compulsorily detained"
}
}
]
}
]
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"identified_line": {
"line": "* Recurrent or progressive advanced breast cancer (locally-advanced or metastatic)",
"criterions": [
{
"exact_snippets": "Recurrent or progressive advanced breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"recurrent",
"progressive",
"advanced"
]
}
},
{
"exact_snippets": "locally-advanced or metastatic",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"locally-advanced",
"metastatic"
]
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Recurrent or progressive advanced breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"recurrent",
"progressive",
"advanced"
]
}
},
{
"or_criteria": [
{
"exact_snippets": "locally-advanced or metastatic",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "stage",
"expected_value": "locally-advanced"
}
},
{
"exact_snippets": "locally-advanced or metastatic",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "stage",
"expected_value": "metastatic"
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "* Documented breast cancer with tumor ≤ 28 days prior to study entry",
"criterions": [
{
"exact_snippets": "Documented breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "documentation",
"expected_value": true
}
},
{
"exact_snippets": "tumor ≤ 28 days prior to study entry",
"criterion": "tumor",
"requirement": {
"requirement_type": "time since documentation",
"expected_value": {
"operator": "<=",
"value": 28,
"unit": "days"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Documented breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "documentation",
"expected_value": true
}
},
{
"exact_snippets": "tumor \u0010 28 days prior to study entry",
"criterion": "tumor",
"requirement": {
"requirement_type": "time since documentation",
"expected_value": {
"operator": "<=",
"value": 28,
"unit": "days"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Women who are NOT of childbearing potential",
"criterions": [
{
"exact_snippets": "Women who are NOT of childbearing potential",
"criterion": "childbearing potential",
"requirement": {
"requirement_type": "status",
"expected_value": "NOT of childbearing potential"
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
},
{
"identified_line": {
"line": "* Must be able to take oral medication",
"criterions": [
{
"exact_snippets": "Must be able to take oral medication",
"criterion": "ability to take oral medication",
"requirement": {
"requirement_type": "ability",
"expected_value": true
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
},
{
"identified_line": {
"line": "* Performance Status 0 or 1",
"criterions": [
{
"exact_snippets": "Performance Status 0 or 1",
"criterion": "Performance Status",
"requirement": {
"requirement_type": "value",
"expected_value": [
"0",
"1"
]
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
}
],
"failed_exclusion": [
{
"identified_line": {
"line": "* Pleural or pericardial effusion or ascites (of any etiology; Grade ≥ 1) within 6 months prior to study entry",
"criterions": [
{
"exact_snippets": "Pleural or pericardial effusion or ascites",
"criterion": "pleural effusion",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Pleural or pericardial effusion or ascites",
"criterion": "pericardial effusion",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Pleural or pericardial effusion or ascites",
"criterion": "ascites",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Grade ≥ 1",
"criterion": "effusion or ascites grade",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "Grade"
}
}
},
{
"exact_snippets": "within 6 months prior to study entry",
"criterion": "effusion or ascites occurrence time",
"requirement": {
"requirement_type": "time frame",
"expected_value": "within 6 months prior to study entry"
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
},
{
"identified_line": {
"line": "* Prior exposure to exemestane, any Src-family kinase inhibitor including dasatinib, to agents intended to control osteolytic disease other than bisphosphonates, or to any investigational agent for breast cancer",
"criterions": [
{
"exact_snippets": "Prior exposure to exemestane",
"criterion": "prior exposure to exemestane",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Prior exposure to ... any Src-family kinase inhibitor including dasatinib",
"criterion": "prior exposure to Src-family kinase inhibitor",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Prior exposure to ... agents intended to control osteolytic disease other than bisphosphonates",
"criterion": "prior exposure to agents intended to control osteolytic disease other than bisphosphonates",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Prior exposure to ... any investigational agent for breast cancer",
"criterion": "prior exposure to investigational agent for breast cancer",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Prior exposure to exemestane",
"criterion": "prior exposure to exemestane",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Prior exposure to ... any Src-family kinase inhibitor including dasatinib",
"criterion": "prior exposure to Src-family kinase inhibitor",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Prior exposure to ... agents intended to control osteolytic disease other than bisphosphonates",
"criterion": "prior exposure to agents intended to control osteolytic disease other than bisphosphonates",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Prior exposure to ... any investigational agent for breast cancer",
"criterion": "prior exposure to investigational agent for breast cancer",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Pregnant Women and Women of Childbearing Potential (WOCBP)",
"criterions": [
{
"exact_snippets": "Pregnant Women",
"criterion": "pregnancy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Women of Childbearing Potential (WOCBP)",
"criterion": "childbearing potential",
"requirement": {
"requirement_type": "status",
"expected_value": "women of childbearing potential"
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Pregnant Women",
"criterion": "pregnancy",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Women of Childbearing Potential (WOCBP)",
"criterion": "childbearing potential",
"requirement": {
"requirement_type": "status",
"expected_value": "women of childbearing potential"
}
}
]
}
}
],
"failed_miscellaneous": []
}